Incidence, Prevalence, and Stability of Remission in Individuals With Clinical High Risk for Psychosis
clinical high risk
North American Prodromal
American Prodromal Longitudinal
remission
symptoms
Grip Strength as a Marker of Resting-State Network Integrity and Well-Being in Early Psychosis
Cognitive Neuroscience
Neuroimaging
Schizophrenia Spectrum and Other Psychotic Disorders
The electroencephalography protocol for the Accelerating Medicines Partnership(r) Schizophrenia Program: Reliability and stability of measures
low conversion rates
AMP SCZ EEG
AMP SCZ
Accelerating Medicines Partnership
clinical high risk
Digital health technologies in the accelerating medicines Partnership(r) Schizophrenia Program
Clinical High Risk
Clinical High
High Risk
Digital
Digital phenotyping
Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership(r) Schizophrenia Program: design considerations
proteomic assay methodologies
Accelerating Medicines Partnership
assay methodologies
methodologies and genomics
genomics have significantly
Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership(r) Schizophrenia Program
Medicines Partnership Schizophrenia
Accelerating Medicines Partnership
Partnership Schizophrenia
Accelerating Medicines
Medicines Partnership
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership(r) Schizophrenia Program
Accelerating Medicines Partnership
Outcome Measures Team
Clinical
AMP SCZ
AMP SCZ project
Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership(r) Schizophrenia Program
Modern research management
publicly funded studies
data governance model
Modern research
data
Data analysis strategies for the Accelerating Medicines Partnership(r) Schizophrenia Program
Accelerating Medicines Partnership
Medicines Partnership
Accelerating Medicines
AMP SCZ project
AMP SCZ
The MR neuroimaging protocol for the Accelerating Medicines Partnership(r) Schizophrenia Program
clinical high risk
forecast clinical outcomes
understanding potential brain
potential brain regions
studies involving MRI
Cognitive assessment in the Accelerating Medicines Partnership(r) Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
clinical high risk
contributes unique variance
multivariate prediction models
Cognitive impairment occurs
Accelerating Medicines Partnership
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS
ascertainment
clinical high risk
early detection
psychometrics
severity rating
Adverse Outcome Following Mild Traumatic Brain Injury Is Associated with Microstructure Alterations at the Gray and White Matter Boundary
cognitive impairment
diffusion tensor imaging
fractional anisotropy
magnetic resonance imaging
mild traumatic brain injury
post-concussion symptoms
Exploring the impact of hippocampal sclerosis on white matter tracts memory in individuals with mesial temporal lobe epilepsy
cognitive impairment
focal epilepsy
magnetic resonance imaging
white matter tracts
No matching items